Results of a UK real world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory large B-cell lymphoma.

Northend, Michael, Wilson, William, Osborne, Wendy, Fox, Christopher P, Davies, Andrew John, El-Sharkawi, Dima, Phillips, Elizabeth H, Sim, Hau Wui, Sadullah, Shalal, Shah, Nimish, Peng, Ying Ying, Qureshi, Iman, Addada, Juanah, Mora, Rocio Figueroa, Phillips, Neil, Kuhnl, Andrea, Davies, Elizabeth, Wrench, David J, McKay, Pamela, Karpha, Indrani, Cowley, Anna, Karim, Richard, Challenor, Sarah, Singh, Vikram, Burton, Catherine, Auer, Rebecca, Williams, Chris, Cunningham, Joel, Broom, Angus, Arasaretnam, Anita, Roddie, Claire, Menne, Tobias and Townsend, William M (2022) Results of a UK real world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory large B-cell lymphoma. Blood advances. ISSN 2473-9537. This article is available to all UHB staff and students login using a UHB Athens Account. Register for Athens here - https://openathens.nice.org.uk/

Full text not available from this repository.
Official URL: https://ashpublications.org/bloodadvances

Abstract

The addition of polatuzumab vedotin to bendamustine and rituximab (Pola-BR) has been shown to improve overall survival (OS) in stem cell transplant (SCT)-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). It is also increasingly used as bridging to CAR T-cell therapy (CAR-T). We retrospectively analysed the efficacy of Pola-BR in 133 patients at 28 UK institutions. Treatment intent was bridging to CAR-T for N=40, re-induction with planned SCT for N=13 and stand-alone treatment for N=78. The overall response rate (ORR) was 57.0% (complete response (CR) 32.8%). After median 7.7 months follow-up, median PFS and OS were 4.8 months and 8.2 months respectively. For stand-alone treatment shortened PFS was associated with bulk disease (>7.5cm) (HR 2.32 (95% CI 1.23-4.38), p=0.009), >1 prior treatment (HR 2.17 (95% CI 1.19-3.95), p=0.01) and refractoriness to the last treatment (HR 3.48 (95% CI 1.79-6.76), p<0.001). For CAR-T bridging the ORR was 42.1% (CR 18.4%) and for treatment after CAR-T failure the ORR was 43.8% (CR 18.8%). These data demonstrate efficacy for Pola-BR as a treatment for SCT-ineligible patients with R/R DLBCL, help to delineate which patients may benefit most, and provide preliminary evidence of efficacy as bridging to CAR-T and after CAR-T failure.

Item Type: Article
Additional Information: This article is available to all UHB staff and students login using a UHB Athens Account. Register for Athens here - https://openathens.nice.org.uk/
Subjects: QZ Pathology. Oncology
WH Haemic and lymphatic systems. Haematology
Divisions (November 2021 Onwards): Haematology
Oncology
Related URLs:
Depositing User: Lotty Summers
Date Deposited: 19 Jan 2022 12:28
Last Modified: 19 Jan 2022 12:28
URI: http://www.repository.uhblibrary.co.uk/id/eprint/5101

Actions (login required)

View Item View Item